Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 3.8
(1.33%)
SEK 3.8
(1.33%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -326.9 Million SEK | -72.51% |
| 2022 | -189.5 Million SEK | -80.94% |
| 2021 | -104.73 Million SEK | 41.53% |
| 2020 | -179.12 Million SEK | -191.59% |
| 2019 | -61.42 Million SEK | 27.73% |
| 2018 | -85 Million SEK | 3.33% |
| 2017 | -87.93 Million SEK | -130.06% |
| 2016 | -38.22 Million SEK | 12.8% |
| 2015 | -43.83 Million SEK | 9.47% |
| 2014 | -48.42 Million SEK | -89.52% |
| 2013 | -25.54 Million SEK | 24.54% |
| 2012 | -33.85 Million SEK | -1.84% |
| 2011 | -33.24 Million SEK | -774.75% |
| 2010 | -3.8 Million SEK | -182.44% |
| 2009 | -1.34 Million SEK | -140.7% |
| 2008 | -559.06 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -71.9 Million SEK | 4.13% |
| 2024 Q1 | -75 Million SEK | 13.09% |
| 2023 FY | -326.9 Million SEK | -72.51% |
| 2023 Q2 | -79.5 Million SEK | -6.57% |
| 2023 Q1 | -74.6 Million SEK | 3.74% |
| 2023 Q3 | -86.2 Million SEK | -8.43% |
| 2023 Q4 | -86.3 Million SEK | -0.12% |
| 2022 Q1 | -28.2 Million SEK | 0.57% |
| 2022 FY | -189.5 Million SEK | -80.94% |
| 2022 Q4 | -77.5 Million SEK | -47.9% |
| 2022 Q3 | -52.4 Million SEK | -66.31% |
| 2022 Q2 | -31.5 Million SEK | -11.69% |
| 2021 Q2 | -34.32 Million SEK | -77.72% |
| 2021 Q3 | -22.53 Million SEK | 34.36% |
| 2021 Q4 | -28.37 Million SEK | -25.93% |
| 2021 Q1 | -19.31 Million SEK | 74.39% |
| 2021 FY | -104.73 Million SEK | 41.53% |
| 2020 Q2 | -36.16 Million SEK | 15.54% |
| 2020 FY | -179.12 Million SEK | -191.59% |
| 2020 Q4 | -75.41 Million SEK | -204.98% |
| 2020 Q1 | -42.81 Million SEK | -86.12% |
| 2020 Q3 | -24.72 Million SEK | 31.63% |
| 2019 Q1 | 22.89 Million SEK | 203.4% |
| 2019 FY | -61.42 Million SEK | 27.73% |
| 2019 Q2 | -29.41 Million SEK | -228.49% |
| 2019 Q3 | -31.89 Million SEK | -8.44% |
| 2019 Q4 | -23 Million SEK | 27.87% |
| 2018 Q3 | -18.84 Million SEK | 33.2% |
| 2018 Q4 | -22.13 Million SEK | -17.48% |
| 2018 FY | -85 Million SEK | 3.33% |
| 2018 Q1 | -15.81 Million SEK | 50.79% |
| 2018 Q2 | -28.21 Million SEK | -78.43% |
| 2017 FY | -87.93 Million SEK | -130.06% |
| 2017 Q4 | -32.12 Million SEK | -17.52% |
| 2017 Q3 | -27.33 Million SEK | -68.87% |
| 2017 Q2 | -16.18 Million SEK | -31.82% |
| 2017 Q1 | -12.28 Million SEK | -7.15% |
| 2016 Q1 | -6.84 Million SEK | 22.3% |
| 2016 FY | -38.22 Million SEK | 12.8% |
| 2016 Q4 | -11.46 Million SEK | -44.5% |
| 2016 Q3 | -7.93 Million SEK | 33.81% |
| 2016 Q2 | -11.98 Million SEK | -75.05% |
| 2015 Q3 | -11.43 Million SEK | 0.02% |
| 2015 FY | -43.83 Million SEK | 9.47% |
| 2015 Q1 | -12.15 Million SEK | 31.37% |
| 2015 Q2 | -11.43 Million SEK | 5.91% |
| 2015 Q4 | -8.81 Million SEK | 22.92% |
| 2014 Q2 | -12.67 Million SEK | -87.07% |
| 2014 Q1 | -6.77 Million SEK | 2.67% |
| 2014 Q4 | -17.7 Million SEK | -57.18% |
| 2014 Q3 | -11.26 Million SEK | 11.12% |
| 2014 FY | -48.42 Million SEK | -89.52% |
| 2013 Q2 | -6.04 Million SEK | 24.7% |
| 2013 FY | -25.54 Million SEK | 24.54% |
| 2013 Q4 | -6.96 Million SEK | -54.38% |
| 2013 Q3 | -4.5 Million SEK | 25.45% |
| 2013 Q1 | -8.03 Million SEK | 4.27% |
| 2012 Q2 | -10.54 Million SEK | -13.7% |
| 2012 FY | -33.85 Million SEK | -1.84% |
| 2012 Q4 | -8.39 Million SEK | -48.71% |
| 2012 Q3 | -5.64 Million SEK | 46.51% |
| 2012 Q1 | -9.27 Million SEK | 63.51% |
| 2011 Q2 | -2.48 Million SEK | 12.61% |
| 2011 Q1 | -2.84 Million SEK | -76.93% |
| 2011 Q4 | -25.42 Million SEK | -923.25% |
| 2011 FY | -33.24 Million SEK | -774.75% |
| 2011 Q3 | -2.48 Million SEK | 0.14% |
| 2010 Q2 | -755.13 Thousand SEK | -43.45% |
| 2010 Q1 | -526.42 Thousand SEK | 0.0% |
| 2010 Q4 | -1.6 Million SEK | -76.86% |
| 2010 FY | -3.8 Million SEK | -182.44% |
| 2010 Q3 | -909.86 Thousand SEK | -20.49% |
| 2009 FY | -1.34 Million SEK | -140.7% |
| 2008 FY | -559.06 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | -613.755% |
| Biovica International AB (publ) | -124.82 Million SEK | -161.891% |
| Cantargia AB (publ) | -280.02 Million SEK | -16.739% |
| CombiGene AB (publ) | -35.66 Million SEK | -816.575% |
| Cyxone AB (publ) | -22.98 Million SEK | -1321.984% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -2699.281% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -1893.539% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -257.655% |
| Fluicell AB (publ) | -26.55 Million SEK | -1131.076% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -165.626% |
| Mendus AB (publ) | -101.61 Million SEK | -221.692% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -781.821% |
| I-Tech AB | 20.2 Million SEK | 1718.077% |
| Intervacc AB (publ) | -102.85 Million SEK | -217.835% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -2595.416% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 2786.334% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -1726.563% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1955.716% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -74534.703% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 15.785% |
| Lipum AB (publ) | -37.17 Million SEK | -779.283% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | -31.504% |
| Ziccum AB (publ) | -21.41 Million SEK | -1426.714% |
| BioArctic AB (publ) | 229.24 Million SEK | 242.596% |
| Genovis AB (publ.) | 61.5 Million SEK | 631.545% |
| Camurus AB (publ) | 431.44 Million SEK | 175.769% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | -83.818% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -475.315% |
| Aptahem AB (publ) | -11.11 Million SEK | -2841.635% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | -5.132% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | -81.948% |
| Kancera AB (publ) | -64.88 Million SEK | -403.783% |
| Saniona AB (publ) | -95.81 Million SEK | -241.196% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -674.223% |
| AcouSort AB (publ) | -17.08 Million SEK | -1812.926% |
| Xintela AB (publ) | -54.08 Million SEK | -504.441% |
| Abliva AB (publ) | -95.5 Million SEK | -242.271% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 6169.439% |
| Amniotics AB (publ) | -30.87 Million SEK | -958.957% |
| 2cureX AB (publ) | -32.51 Million SEK | -905.289% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -2448.332% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 29.878% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 60.696% |
| Biosergen AB | -27.03 Million SEK | -1109.084% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -1878.454% |
| Corline Biomedical AB | -1.8 Million SEK | -17970.757% |
| NextCell Pharma AB | -41.95 Million SEK | -679.079% |
| Nanologica AB (publ) | -75.15 Million SEK | -334.956% |
| LIDDS AB (publ) | -40.2 Million SEK | -713.063% |
| BioInvent International AB (publ) | -330.3 Million SEK | 1.031% |
| SynAct Pharma AB | -215.81 Million SEK | -51.476% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -642.044% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -1277.175% |
| Alzinova AB (publ) | -16.48 Million SEK | -1883.617% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -199.118% |
| Oncopeptides AB (publ) | -249.11 Million SEK | -31.227% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -3192.041% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -188.467% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -1449.95% |
| Simris Alg AB (publ) | -37.3 Million SEK | -776.29% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -115.278% |